Ascelia Pharma 2024 H1 Results - Orviglance Phase 3 Success

Ascelia Pharma presented its H1 2024 results highlighting the successful completion of Phase 3 clinical development for Orviglance®. The presentation covers quarterly financial performance, recent milestones, and the company's pipeline strategy in orphan oncology focused on delivering targeted cancer treatments.